K
Kenji Tomii
Researcher at Nagasaki University
Publications - 3
Citations - 705
Kenji Tomii is an academic researcher from Nagasaki University. The author has contributed to research in topics: Internal medicine & Interstitial lung disease. The author has an hindex of 1, co-authored 1 publications receiving 595 citations.
Papers
More filters
Journal ArticleDOI
Facile Discrimination of Aldose Enantiomers by Reversed-Phase HPLC
TL;DR: The reaction was applied to the determination of absolute configuration the sugar residues of an aroma precursor and direct HPLC analysis of the reaction mixture and UV detection at 250 nm discriminated D- and L-enantiomers of aldoses.
Proceedings ArticleDOI
Nationwide prospective registry of idiopathic interstitial pneumonias with central multidisciplinary diagnosis in Japan (JIPS Registry): Analysis of disease progression
T. Ogura,Ryo Okuda,N Ishikawa,T. Suda,Nana Arai,Takahisa Takihara,Megumi Hamaguchi,Y. Kondoh,Mikio Toyoshima,Kenji Tomii,Musashi Abe,Mitsuro Kato,Michiko Kagajo,Youichi Shimizu,Hirohumi Tomioka,Kodai Kawamura,K. Honda,Yoshimi Nishioka,M Tanigawa,Hironobu Chiba,Shinji Izumi,Kyoko Tobino,Hiroshige Yamauchi,Takesi Kawamura,Makiko Inomata,Koji Usui,Humio Ohkubo,Hidetoshi Matsushima,Y. Oyamada,T Jokoh,Takasi Arai,Tae Iwasawa,Fumikazu Sakai,S. Morita,Noboru Ichihara,Toshihiro Nukiwa,K. Kobayashi,J. Registry Members +37 more
TL;DR: In this paper , progression-free survival (PFS) and the percentage of cases meeting progressive fibrosing interstitial lung disease (PF-ILD) criteria were longitudinally investigated.
Proceedings ArticleDOI
Respiratory lesions of IgG4-related disease classified by 2019 ACR/EULAR criteria: A retrospective study
Masamichi Komatsu,Hisae Yamamoto,Shoko Matsui,Yasunori Terasaki,Akira Hebisawa,T. Iwasawa,Takeshi Johkoh,Tomohisa Baba,A. Miyamoto,Takaya Handa,Kenji Tomii,Yoshibumi Waseda,Masashi Bando,H. Ishii,Yoshiji Miyazaki,Atsuhiko Yoshizawa,T. Takemura,Yasuto Kawabata,Mio Hanaoka,T. Ogura +19 more
TL;DR: In this paper , the characteristics of patients with IgG4+ interstitial lung disease (ILD) according to the American College of Rheumatology and European League Against Rheumatism classification criteria for IG4-related disease (RD) were assessed.